8 completed. 8 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 8 |
| Phase 2 | 3 | Completed 3 |
Follow S-Adenosylmethionine: new trials by email Literature Review of S-Adenosylmethionine trials Research Report on S-Adenosylmethionine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy Study Of Tofacitinib In Pediatric JIA Population CP-690,550 (tofacitinib), placebo - Juvenile Idiopathic Arthritis | Phase 3 | Completed | Pfizer | 225 | 2016-06-10 | 2020-04-13 |
| Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption Ademetionine IV+tablet, Ademetionine tablet - Intrahepatic Cholestasis Associated With Alcoholic Liver Disease | Phase 3 | Completed | Abbott | 75 | 2014-06-01 | 2015-06-16 |
| Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group SAMe 1000 mg, SAMe 1500 mg, SAMe 2000 mg - Non Alcoholic Fatty Liver Disease | Phase 3 | Completed | Abbott | 108 | 2012-12-01 | 2016-02-19 |
| S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence S-Adenosyl-L-Methionine, placebo - Tobacco Dependence | Phase 2 / Phase 3 | Completed | Mayo Clinic | 150 | 2008-09-01 | 2011-09-09 |
| Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine S-adenosyl-L-methionine, betaine, pegylated interferon alpha2b - Hepatitis C | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 30 | 2006-08-01 | 2010-10-28 |
| Effects of SAMe in Patients With Alcoholic Liver Disease S-adenosylmethionine, Placebo - Liver Disease, Alcoholic | Phase 3 | Completed | University of California, Davis | 94 | 2005-09-01 | 2017-05-30 |
| S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis S-adenosylmethionine - Hepatitis | Phase 3 | Completed | US Department of Veterans Affairs | 2004-01-01 | 2009-01-21 | |
| SAM-e for the Treatment of Depression in Patients With Parkinson's Disease SAM-e, oral escitalopram, placebo - Parkinson's Disease, Depression | Phase 2 / Phase 3 | Completed | NYU Langone Health | 29 | 2003-07-01 | 2016-07-13 |
Fatty Liver (2) · Non-alcoholic Fatty Liver Disease (2) · Arthritis (1) · Arthritis, Juvenile (1) · Cholestasis, Intrahepatic (1) · Depression (1) · Hepatitis (1) · Hepatitis C (1) · Liver Diseases, Alcoholic (1) · Obesity (1) · Parkinson Disease (1) · Tobacco Use (1) · Tobacco Use Disorder (1)
Abbott (2) · Mayo Clinic (1) · NYU Langone Health (1) · Pfizer (1) · US Department of Veterans Affairs (1) · University Hospital, Basel, Switzerland (1) · University of California, Davis (1)
United States (5) · Russia (3) · Poland (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Mexico (1) · Spain (1) · Switzerland (1) · Turkey (Türkiye) (1)
Suntje Sander-Struckmeier, PhD (2) · Alessandro Di Rocco, MD (1) · Amit Sood, M.D. (1) · Charles H Halsted, MD (1) · Markus H Heim, MD (1)
PMID 20561703, PMID 21079746, PMID 22044287, PMID 34767764, PMID 37230961, PMID 38298058, PMID 40312101
2015 (1), R01AA014562 (1), R01AT000941 (1)